The Correlation Of Simva Statin Intervention Carotid Atheroslerosis,Hign-Sensitivity C-Reactive Protein And Cerebrovascular Clinical Events

ObjectiveIschemic cerebrovascular disease is the basic cause of atherosclerosis (AS).Clinical events leading to cerebral blood vessels is mainly due to atherosclerotic plaque rupture and thrombosis.The plaque rupture depends on plaque vulnerability,and with peripheral blood levels of hs-CRP are closely related. As plaque dyslipidemia are important risk factors that affect plaque stability is the external factors that could lead to hardening stress-induced blood vessel inflammation and hemodynamic abnormalities. While simvastatin can regulate blood fat, improve endothelial function and reduce hs-CRP levels, stability and reverse the plaque, thereby reducing the occurrence of cerebrovascular events. The issue on carotid atherosclerosis were treated with simvastatin treatment, to study the morphology of carotid artery ultrasound before and after treatment and changes in ultrasonic echo characteristics, and hs-CRP levels in peripheral blood, and to explore Simvastatin carotid atherosclerosis, hs-CRP and the effect on cerebrovascular clinical events. And with peripheral blood levels of hs-CRP are closely related.MethodsOut-patient health check on carotid artery ultrasound confirmed carotid atherosclerosis were randomly divided into two groups, while testing the peripheral blood of hs-CRP levels in the control group: treatment and improvement of the food only way of life; treatment Group: In addition to the above, plus simvastatin 20mg / d, the two groups in control of blood pressure, blood glucose, smoking cessation, antiplatelet therapy, and so exactly the same. Treatment after six months, review the carotid artery ultrasound and blood levels of hs-CRP were observed before and after treatment, and treatment of carotid artery intima between the two groups in membrane (CIMT), plaque area, ultrasound characteristics, hs-CRP levels and serum lipid levels, and compare the two groups were followed up for six months of clinical events occurred in the risk of cerebrovascular.ResultsThe control group before and after treatment CIMT,plaque area,hs-CRP levels were not significantly reduce the P> 0.05; treatment group before and after treatment were significantly different P <0.05;two groups after treatment were significantly different P <0.05;end of the treatment groups of cerebral vascular clinical events were significantly different compared P <0.05.ConclusionsAs a lipid-lowering drug simvastatin, not only blood lipid, can also reduce hs-CRP levels, reduced plaque area, stability and reverse the plaque, and reduced carotid atherosclerosis in patients with ischemic cerebrovascular event risk, the prevention of ischemic stroke to provide the theoretical basis and interventions.